doxazosin has been researched along with Urethral Obstruction in 4 studies
Doxazosin: A prazosin-related compound that is a selective alpha-1-adrenergic blocker.
doxazosin : A member of the class of quinazolines that is quinazoline substituted by an amino group at position 4, methoxy groups at positions 6 and 7 and a piperazin-1-yl group at position 2 which in turn is substituted by a 2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl group at position 4. An antihypertensive agent, it is used in the treatment of high blood pressure.
Urethral Obstruction: Partial or complete blockage in any part of the URETHRA that can lead to difficulty or inability to empty the URINARY BLADDER. It is characterized by an enlarged, often damaged, bladder with frequent urges to void.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the urodynamic effects of fesoterodine, a new antimuscarinic agent, alone and combined with doxazosin, in a rat model of partial urethral obstruction (PUO), as 35-83% of men with bladder outlet obstruction (BOO) secondary to benign prostatic hyperplasia (BPH) have overactive bladder (OAB) syndrome, and as the combination of alpha(1)-adrenoceptor- and muscarinic-receptor antagonists has been proposed to be beneficial for these patients." | 7.76 | Urodynamic evaluation of fesoterodine metabolite, doxazosin and their combination in a rat model of partial urethral obstruction. ( Andersson, KE; Brodsky, M; Christ, GJ; Füllhase, C; Gratzke, C; Soler, R, 2010) |
| " We assessed the effects of intrathecal 5-hydroxymethyl tolterodine, an active metabolite of fesoterodine, in obstructed and nonobstructed rats, and of combined intrathecal 5-hydroxymethyl tolterodine/doxazosin in a rat model of partial urethral obstruction." | 7.76 | Spinal effects of the fesoterodine metabolite 5-hydroxymethyl tolterodine and/or doxazosin in rats with or without partial urethral obstruction. ( Andersson, KE; Brodsky, M; Christ, GJ; Füllhase, C; Gratzke, C; Soler, R, 2010) |
| " We assessed the effects of intrathecal 5-hydroxymethyl tolterodine, an active metabolite of fesoterodine, in obstructed and nonobstructed rats, and of combined intrathecal 5-hydroxymethyl tolterodine/doxazosin in a rat model of partial urethral obstruction." | 3.76 | Spinal effects of the fesoterodine metabolite 5-hydroxymethyl tolterodine and/or doxazosin in rats with or without partial urethral obstruction. ( Andersson, KE; Brodsky, M; Christ, GJ; Füllhase, C; Gratzke, C; Soler, R, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kirpatovskii, VI | 1 |
| Mudraya, IS | 1 |
| Revenko, SV | 1 |
| Bablumyan, AY | 1 |
| Adamyan, NK | 1 |
| Ivanov, VP | 1 |
| Füllhase, C | 2 |
| Soler, R | 2 |
| Gratzke, C | 2 |
| Brodsky, M | 2 |
| Christ, GJ | 2 |
| Andersson, KE | 2 |
| Esteban Fuertes, M | 1 |
| Salinas Casado, J | 1 |
| Virseda Chamorro, M | 1 |
| Ramírez Fernández, JC | 1 |
| Salomon Moh'd, S | 1 |
| Luengo Alpuente, S | 1 |
| Resel Estévez, L | 1 |
4 other studies available for doxazosin and Urethral Obstruction
| Article | Year |
|---|---|
Effect of Doxazosin on Autonomic Nervous Control and Urodynamics of Rat Urinary Bladder during Modeled Infravesical Obstruction.
Topics: Adrenergic alpha-1 Receptor Antagonists; Animals; Doxazosin; Drug Evaluation, Preclinical; Female; M | 2016 |
Urodynamic evaluation of fesoterodine metabolite, doxazosin and their combination in a rat model of partial urethral obstruction.
Topics: Adrenergic alpha-Antagonists; Animals; Benzhydryl Compounds; Doxazosin; Drug Therapy, Combination; M | 2010 |
Spinal effects of the fesoterodine metabolite 5-hydroxymethyl tolterodine and/or doxazosin in rats with or without partial urethral obstruction.
Topics: Adrenergic alpha-Antagonists; Animals; Benzhydryl Compounds; Cresols; Doxazosin; Drug Therapy, Combi | 2010 |
[Doxazosin treatment of disorders of the voiding phase in benign prostatic hyperplasia].
Topics: Adrenergic alpha-Antagonists; Aged; Doxazosin; Humans; Male; Middle Aged; Muscle Contraction; Prospe | 1997 |